NSE: ACUTAAS · 28 October 2026
- Acutaas Chemicals has risen 10.19% over 2 trading sessions; today's move is -2.72%.
- Acutaas Chemicals reported a 42.7% year-on-year rise in quarterly revenue to ₹4,369 million for Q2 FY27, driven by strong performance in its Pharmaceutical Intermediates segment. Profit after tax grew 71.4% year-on-year to ₹1,231 million, backed by an improved gross margin of 62.1% and an EBITDA margin of 40.3%. Management also raised its FY27 revenue growth guidance to around 30% and upgraded EBITDA margin guidance to the 38-40% range.
- Trading volume was 3.43 times the 20-day average daily volume.
Acutaas Chemicals share price: 10.19% rise over 2 trading sessions
Acutaas Chemicals Ltd. (ACUTAAS) moved lower in the session on October 28, 2026, falling 2.72% to close at ₹3,690.10 compared to its previous close of ₹3,793.30. The stock opened at ₹3,856.20 and experienced an intraday range between a low of ₹3,689.10 and a high of ₹3,973.90, ultimately finishing near the lower end of its daily spread.
The broader market and sector benchmarks recorded minor declines on the trading day, with the Nifty falling 0.22% and the Nifty Metal sector benchmark dropping 0.32%. Against this modest downward market backdrop, Acutaas Chemicals' 2.72% pullback followed a strong multi-day advance where the stock registered gains of 13.27% in the prior trading session and 20.89% over the last two sessions, alongside a 17.06% return over the past 5 trading days and 14.80% over the past 20 trading days.
The recent price action coincides with the company's Q2 and H1 FY27 financial results reported on October 27, 2026, where management posted a 42.70% year-on-year increase in revenue to ₹4,369 million and a 71.40% jump in profit after tax to ₹1,231 million. Additionally, management revised its FY27 revenue growth guidance upward from 25% to around 30% and elevated its EBITDA margin guidance to a 38-40% range following strong momentum in pharmaceutical intermediates and the early inauguration of its South Korea semiconductor chemicals manufacturing facility. While these fundamental updates provide important context regarding the company's operating performance, today's decline appears consistent with profit-taking after the stock's recent sharp outperformance.
21.27 lakh shares traded by 28 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 6.20 lakh shares (3.43 times). The five-day average daily volume was 13.91 lakh shares. Separately, the NSE report for 27 October 2026 showed 10.07 lakh shares delivered, representing 21.21% of that day’s traded volume. The same report recorded 345,689 trades.
The stock declined 2.72% despite strong volume and recent positive earnings announcements, reflecting natural profit-taking after sharp prior-session returns of 13.27% and a 5-day gain of 17.06%.
Latest Company Developments
Acutaas Chemicals reported a 42.7% year-on-year rise in quarterly revenue to ₹4,369 million for Q2 FY27, driven by strong performance in its Pharmaceutical Intermediates segment. Profit after tax grew 71.4% year-on-year to ₹1,231 million, backed by an improved gross margin of 62.1% and an EBITDA margin of 40.3%. Management also raised its FY27 revenue growth guidance to around 30% and upgraded EBITDA margin guidance to the 38-40% range.
The earnings beat and guidance upgrade provide direct insight into the company's operational strength and medium-term growth trajectory.
The company completed the acquisition of 100% equity share capital of its step-down subsidiary, Enchem Ami Organics Private Limited, through the transfer of 10,000 equity shares from Acutaas Chemicals Electrolytes Private Limited. Consequently, Enchem Ami Organics has become a direct wholly-owned subsidiary of the company.
Simplifies corporate structure and consolidates ownership in the electrolyte and specialized chemical subsidiary.
At the 19th Annual General Meeting held on September 24, 2026, shareholders approved the re-appointment of Mr. Ram Mohan Lokhande as Whole Time Director for a five-year term effective February 8, 2027. Shareholders also approved the second term re-appointment of Mrs. Anita Bandyopadhyay as Non-Executive Independent Director for five consecutive years starting February 8, 2027.
Ensures leadership and governance continuity for key technical and oversight roles.
a press release dated October 27, 2026, titled "Q2 & H1 FY27 Results".
Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.44% on 30 September 2026. This compares with 14.17% on 30 June 2026, a change of +0.27 percentage points.
The filing reported 32 MF/UTI holders.
What to Watch Next
- Execution of the upgraded FY27 revenue growth guidance of around 30%
- ramp-up and commercial production progress at the newly inaugurated South Korea manufacturing facility
- sustained delivery volume and cash market participation relative to the 20-day average volume
- performance trends in the specialty chemicals and pharmaceutical intermediates segments
Other Dated Coverage
- Acutaas Chemicals Share Price Today: Rises 20.98% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
- Acutaas Chemicals Share Price Today: Why ACUTAAS Is Rising 6.73% | 26 October 2026 — 26 October 2026
More Acutaas Chemicals news and dated analysis →
Frequently Asked Questions
What is the latest Acutaas Chemicals company news?
Acutaas Chemicals reported a 42.7% year-on-year rise in quarterly revenue to ₹4,369 million for Q2 FY27, driven by strong performance in its Pharmaceutical Intermediates segment. Profit after tax grew 71.4% year-on-year to ₹1,231 million, backed by an improved gross margin of 62.1% and an EBITDA margin of 40.3%. Management also raised its FY27 revenue growth guidance to around 30% and upgraded EBITDA margin guidance to the 38-40% range.
How strong was Acutaas Chemicals’s trading volume?
21.27 lakh shares traded, 3.43 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.